ProfileGDS5678 / 1437957_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 61% 60% 63% 60% 59% 65% 64% 60% 61% 60% 61% 60% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6435960
GSM967853U87-EV human glioblastoma xenograft - Control 23.6151961
GSM967854U87-EV human glioblastoma xenograft - Control 33.6072860
GSM967855U87-EV human glioblastoma xenograft - Control 43.7266863
GSM967856U87-EV human glioblastoma xenograft - Control 53.5750360
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6156159
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9574165
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8121264
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5981160
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6162661
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6004660
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6003761
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6138660
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6134661